

Pharmacy Drug Policy Checklist

POLICY NAME

Lenmeldy (atidarsagene autotemcel)

POLICY #

Criteria

Exclusion Criteria – Any of the following prevents coverage	
	 2.1 MLD of any other category or sub-type (such as pre-symptomatic early-juvenile or early-symptomatic early-juvenile) Clinical benefit was not as prevalent or is not supported in these patients and is excluded from coverage.
	 2.2 History of hematopoietic stem cell transplant (HSCT) Patients with prior stem cell transplant were excluded from clinical trials. Safety and efficacy of Lenmeldy in patients with a history of stem cell transplant has not been established and treatment is not recommended in these patients (package insert).
Coverage Criteria	
	 1.1 Diagnosis of metachromatic leukodystrophy (MLD) confirmed by ALL of the following: Molecular genetic testing confirms mutation in the arylsulfatase A (ARSA) gene ARSA activity below the normal range in peripheral blood Elevated sulfatide levels above the normal laboratory reference range
	 1.2 Disease is categorized as pre-symptomatic late infantile (PSLI) as confirmed by disease onset ≤ 30 months and one of the following: Absence of nerve related signs and symptoms of MLD (e.g., peripheral nerve pain, walking difficulties, muscle weakness) Abnormal reflexes or abnormalities on brain magnetic resonance imaging (MRI) and/or nerve conduction tests not associated with functional impairment (e.g., no tremor, no loss of muscle function)
	1.3 Prescribed by or in consultation with a neurologist (nervous system doctor), geneticist (genetic condition doctor), or specialist in the treatment of MLD at an authorized treatment center (authorized treatment centers are defined by the manufacturer)
	1.4 Age less than 18 years
	1.5 Review of clinical information confirming that patient has met all of the above requirements for treatment completed by both a pharmacist and medical director

Referral to Care Coordination		
	4.1 Referral to care coordination will be placed to encourage collaboration with medical management to ensure treatment is received at a qualified treatment center and any appropriate follow-up care is provided CPT Codes HCPCS Codes References	